ANI Pharmaceuticals Inc (ANIP)

Cash ratio

Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Cash and cash equivalents US$ in thousands 221,121 48,228 100,300 7,864 62,332
Short-term investments US$ in thousands
Total current liabilities US$ in thousands 145,477 99,439 87,537 78,565 61,676
Cash ratio 1.52 0.49 1.15 0.10 1.01

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($221,121K + $—K) ÷ $145,477K
= 1.52

The cash ratio measures a company's ability to cover its short-term liabilities with its available cash and cash equivalents. ANI Pharmaceuticals Inc's cash ratio has shown fluctuations over the past five years, ranging from 0.17 to 1.64.

In 2023, the cash ratio has significantly improved to 1.64 compared to the previous year, indicating a stronger ability to cover short-term liabilities with cash reserves. This suggests that ANI Pharmaceuticals Inc has increased its cash holdings relative to its short-term obligations, which may be a positive sign of financial health.

On the other hand, the cash ratio was relatively low in 2020 at 0.17, indicating a potential liquidity risk as the company may have struggled to cover its short-term liabilities with its available cash. However, the cash ratio improved significantly in the following years, reaching 1.27 in 2021 and 1.09 in 2019.

Overall, the trend in ANI Pharmaceuticals Inc's cash ratio shows varying levels of liquidity over the past five years, with improvements in recent years. Investors and stakeholders may find this analysis useful in assessing the company's ability to meet short-term obligations using its cash resources.


Peer comparison

Dec 31, 2023